Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2018, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.
Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 2 and 2 respectively.
Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2018
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) - Overview
Onychomycosis (Tinea Unguium) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Onychomycosis (Tinea Unguium) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
Almirall SA
Blueberry Therapeutics Ltd
Dermala Inc
Eisai Co Ltd
Helix BioMedix Inc
Hexima Ltd
Kaken Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Moberg Pharma AB
NAL Pharmaceuticals Ltd
Novabiotics Ltd
Novan Inc
Viamet Pharmaceuticals Inc
Onychomycosis (Tinea Unguium) - Drug Profiles
BB-0305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Onychomycosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Onychomycosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELS-160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosravuconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-1275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HXP-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ME-1111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitric oxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-3058 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Onychomycosis (Tinea Unguium) - Dormant Projects
Onychomycosis (Tinea Unguium) - Discontinued Products
Onychomycosis (Tinea Unguium) - Product Development Milestones
Featured News & Press Releases
Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
Nov 21, 2017: Hexima Receives Approval to Conduct a Phase 1/2a Study for Fungal Nail Infections
Nov 20, 2017: Moberg Pharma replaces CRO in Phase 3 studies for MOB-015
Nov 08, 2017: Moberg Pharma provides update on timeline for MOB-015
Jul 27, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting
Jun 21, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the 4th International Summit on Nail Diseases
Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
Mar 06, 2017: Viamet Presents Positive Results from Phase 2b Trial of VT-1161 in Onychomycosis at the American Academy of Dermatology Annual Meeting
Mar 01, 2017: Viamet Announces RENOVATE Phase 2b Onychomycosis Results to be Presented at the American Academy of Dermatology 2017 Annual Meeting
Nov 08, 2016: Hallux Announces Start of Phase 2 Clinical Trial
Sep 28, 2016: Moberg Pharma Begins Patient Enrollment in North America and Europe in Two Phase 3 Studies of MOB-015 in Onychomycosis
Aug 10, 2016: Moberg Pharma Announces Approvals to Start Phase 3 Study For MOB-015 In U.S. And Canada
Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
Jul 13, 2016: Viamet to Present Interim RENOVATE Results at the American Podiatric Medical Association 2016 Annual Meeting
Jul 05, 2016: Moberg Pharma announces submission of applications to start Phase 3 studies for MOB-015
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Dermala Inc, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix Inc, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals Inc, H1 2018
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2018
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2018 (Contd..1), H1 2018
Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Global Cephalosporin Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 109
Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections.
Cephalosporin originally derived from The fungus Acremonium, which was previously known as "Cephalosporium".
The global Cephalosporin market was valued at US$ 1380.7 million in 2023 and is anticipated to reach US$ 1346.9 million by 2030, witnessing a CAGR of -0.3% during The forecast period 2024-2030.
Market competition is intense. Qilu Antibiotics, Nectar Lifes......
Global Polymixin Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 120
According to our LPI (LP Information) latest study, the global Polymixin market size was valued at US$ 229.9 million in 2023. With growing demand in downstream market, the Polymixin is forecast to a readjusted size of US$ 291 million by 2030 with a CAGR of 3.4% during review period.
The research report highlights the growth potential of the global Polymixin market. Polymixin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and sup......
Global Sepsis Partnering Market Research Report 2024
Published: 04-Jan-2024 Price: US 2900 Onwards Pages: 78
The Sepsis Partnering market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sepsis Partnering market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape......
Global Cephalosporin Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 156
According to our LPI (LP Information) latest study, the global Cephalosporin market size was valued at US$ 1350.7 million in 2023. With growing demand in downstream market, the Cephalosporin is forecast to a readjusted size of US$ 1319.6 million by 2030 with a CAGR of -0.3% during review period.
The research report highlights the growth potential of the global Cephalosporin market. Cephalosporin are expected to show stable growth in the future market. However, product differentiation, re......
Global Amoxicillin Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 127
According to our LPI (LP Information) latest study, the global Amoxicillin market size was valued at US$ 4512.7 million in 2023. With growing demand in downstream market, the Amoxicillin is forecast to a readjusted size of US$ 5711.7 million by 2030 with a CAGR of 3.4% during review period.
The research report highlights the growth potential of the global Amoxicillin market. Amoxicillin are expected to show stable growth in the future market. However, product differentiation, reducing co......
Global Metronidazole Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 136
According to our LPI (LP Information) latest study, the global Metronidazole market size was valued at US$ 110.5 million in 2023. With growing demand in downstream market, the Metronidazole is forecast to a readjusted size of US$ 106.6 million by 2030 with a CAGR of -0.5% during review period.
The research report highlights the growth potential of the global Metronidazole market. Metronidazole are expected to show stable growth in the future market. However, product differentiation, redu......
Global Drugs for Herpes Labialis (Oral Herpes) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 131
According to our LPI (LP Information) latest study, the global Drugs for Herpes Labialis (Oral Herpes) market size was valued at US$ 2404.5 million in 2023. With growing demand in downstream market, the Drugs for Herpes Labialis (Oral Herpes) is forecast to a readjusted size of US$ 3402.2 million by 2030 with a CAGR of 5.1% during review period.
The research report highlights the growth potential of the global Drugs for Herpes Labialis (Oral Herpes) market. Drugs for Herpes Labialis (Ora......
Global Ampicillin Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 93
According to our LPI (LP Information) latest study, the global Ampicillin market size was valued at US$ 161.6 million in 2023. With growing demand in downstream market, the Ampicillin is forecast to a readjusted size of US$ 194.7 million by 2030 with a CAGR of 2.7% during review period.
The research report highlights the growth potential of the global Ampicillin market. Ampicillin are expected to show stable growth in the future market. However, product differentiation, reducing costs, a......
Global Acinetobacter Infections Treatment Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 101
According to our LPI (LP Information) latest study, the global Acinetobacter Infections Treatment market size was valued at US$ million in 2023. With growing demand in downstream market, the Acinetobacter Infections Treatment is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Acinetobacter Infections Treatment market. Acinetobacter Infections Treatment are expected to show stable ......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
